FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035169670> ?p ?o ?g. }

• W2035169670 endingPage "918" @default.
• W2035169670 startingPage "905" @default.
• W2035169670 abstract "Rapamycin prevention of murine graft-versus-host disease (GVHD) is associated with a shift toward Th2- and Tc2-type cytokines. Recently, we found that use of rapamycin during ex vivo donor Th2 cell generation enhances the ability of adoptively transferred Th2 cells to prevent murine GVHD. In this study, using a method, without antigen-presenting cells, of T-cell expansion based on CD3,CD28 costimulation, we evaluated whether (1) rapamycin preferentially promotes the generation of Th2/Tc2 cells relative to Th1/Tc1 cells, (2) rapamycin-generated T-cell subsets induce cytokine skewing after allogeneic bone marrow transplantation (BMT), and (3) such in vivo cytokine skewing is sensitive to post-BMT rapamycin therapy. Contrary to our hypothesis, rapamycin did not preferentially promote Th2/Tc2 cell polarity, because rapamycin-generated Th1/Tc1 cells secreted type I cytokines (interleukin [IL]-2 and interferon-gamma) did not secrete type II cytokines (IL-4, IL-5, IL-10, or IL-13) and mediated fasL-based cytolysis. Rapamycin influenced T-cell differentiation, because each of the Th1, Th2, Tc1, and Tc2 subsets generated in rapamycin had increased expression of the central-memory T-cell marker, L-selectin (CD62L). Rapamycin-generated Th1/Tc1 and Th2/Tc2 cells were not anergic but instead had increased expansion after costimulation in vitro, increased expansion in vivo after BMT, and maintained full capacity to skew toward type I or II cytokines after BMT, respectively; further, rapamycin-generated Th1/Tc1 cells mediated increased lethal GVHD relative to control Th1/Tc1 cells. Rapamycin therapy after BMT in recipients of rapamycin-generated Th1/Tc1 cells greatly reduced Th1/Tc1 cell number, greatly reduced type I cytokines, and reduced lethal GVHD; in marked contrast, rapamycin therapy in recipients of rapamycin-generated Th2/Tc2 cells nominally influenced the number of Th2/Tc2 cells in vivo and did not abrogate post-BMT type II cytokine skewing. In conclusion, ex vivo and in vivo usage of rapamycin may be used to modulate the post-BMT balance of Th1/Tc1 and Th2/Tc2 cell subsets." @default.
• W2035169670 created "2016-06-24" @default.
• W2035169670 creator A5023596964 @default.
• W2035169670 creator A5026040173 @default.
• W2035169670 creator A5033757387 @default.
• W2035169670 creator A5056262281 @default.
• W2035169670 creator A5069989658 @default.
• W2035169670 creator A5074220802 @default.
• W2035169670 creator A5083240643 @default.
• W2035169670 date "2006-09-01" @default.
• W2035169670 modified "2023-09-27" @default.
• W2035169670 title "Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin Therapy" @default.
• W2035169670 cites W1520527979 @default.
• W2035169670 cites W1533882621 @default.
• W2035169670 cites W1572508860 @default.
• W2035169670 cites W1605178114 @default.
• W2035169670 cites W1949206767 @default.
• W2035169670 cites W1969162956 @default.
• W2035169670 cites W1988718803 @default.
• W2035169670 cites W1989600187 @default.
• W2035169670 cites W1993310853 @default.
• W2035169670 cites W1995511825 @default.
• W2035169670 cites W1999533828 @default.
• W2035169670 cites W2008686731 @default.
• W2035169670 cites W2010665897 @default.
• W2035169670 cites W2014405288 @default.
• W2035169670 cites W2018557026 @default.
• W2035169670 cites W2024795558 @default.
• W2035169670 cites W2032189068 @default.
• W2035169670 cites W2035557966 @default.
• W2035169670 cites W2047260189 @default.
• W2035169670 cites W2049783422 @default.
• W2035169670 cites W2068699102 @default.
• W2035169670 cites W2069075477 @default.
• W2035169670 cites W2069308836 @default.
• W2035169670 cites W2080986723 @default.
• W2035169670 cites W2082167435 @default.
• W2035169670 cites W2084977836 @default.
• W2035169670 cites W2086509092 @default.
• W2035169670 cites W2099736081 @default.
• W2035169670 cites W2107829293 @default.
• W2035169670 cites W2113847305 @default.
• W2035169670 cites W2127793231 @default.
• W2035169670 cites W2143754819 @default.
• W2035169670 cites W2158612356 @default.
• W2035169670 doi "https://doi.org/10.1016/j.bbmt.2006.05.014" @default.
• W2035169670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16920556" @default.
• W2035169670 hasPublicationYear "2006" @default.
• W2035169670 type Work @default.
• W2035169670 sameAs 2035169670 @default.
• W2035169670 citedByCount "46" @default.
• W2035169670 countsByYear W20351696702012 @default.
• W2035169670 countsByYear W20351696702013 @default.
• W2035169670 countsByYear W20351696702014 @default.
• W2035169670 countsByYear W20351696702015 @default.
• W2035169670 countsByYear W20351696702016 @default.
• W2035169670 countsByYear W20351696702019 @default.
• W2035169670 countsByYear W20351696702020 @default.
• W2035169670 countsByYear W20351696702021 @default.
• W2035169670 countsByYear W20351696702022 @default.
• W2035169670 countsByYear W20351696702023 @default.
• W2035169670 crossrefType "journal-article" @default.
• W2035169670 hasAuthorship W2035169670A5023596964 @default.
• W2035169670 hasAuthorship W2035169670A5026040173 @default.
• W2035169670 hasAuthorship W2035169670A5033757387 @default.
• W2035169670 hasAuthorship W2035169670A5056262281 @default.
• W2035169670 hasAuthorship W2035169670A5069989658 @default.
• W2035169670 hasAuthorship W2035169670A5074220802 @default.
• W2035169670 hasAuthorship W2035169670A5083240643 @default.
• W2035169670 hasBestOaLocation W20351696701 @default.
• W2035169670 hasConcept C126322002 @default.
• W2035169670 hasConcept C148125776 @default.
• W2035169670 hasConcept C150903083 @default.
• W2035169670 hasConcept C203014093 @default.
• W2035169670 hasConcept C207001950 @default.
• W2035169670 hasConcept C26291073 @default.
• W2035169670 hasConcept C2776090121 @default.
• W2035169670 hasConcept C2777921159 @default.
• W2035169670 hasConcept C2778690821 @default.
• W2035169670 hasConcept C2911091166 @default.
• W2035169670 hasConcept C502942594 @default.
• W2035169670 hasConcept C71924100 @default.
• W2035169670 hasConcept C86803240 @default.
• W2035169670 hasConcept C8891405 @default.
• W2035169670 hasConceptScore W2035169670C126322002 @default.
• W2035169670 hasConceptScore W2035169670C148125776 @default.
• W2035169670 hasConceptScore W2035169670C150903083 @default.
• W2035169670 hasConceptScore W2035169670C203014093 @default.
• W2035169670 hasConceptScore W2035169670C207001950 @default.
• W2035169670 hasConceptScore W2035169670C26291073 @default.
• W2035169670 hasConceptScore W2035169670C2776090121 @default.
• W2035169670 hasConceptScore W2035169670C2777921159 @default.
• W2035169670 hasConceptScore W2035169670C2778690821 @default.
• W2035169670 hasConceptScore W2035169670C2911091166 @default.
• W2035169670 hasConceptScore W2035169670C502942594 @default.
• W2035169670 hasConceptScore W2035169670C71924100 @default.
• W2035169670 hasConceptScore W2035169670C86803240 @default.
• W2035169670 hasConceptScore W2035169670C8891405 @default.

• next